MESOMARK
MESOMARK, a manual enzyme-linked immunosorbent assay (ELISA), works by identifying serum tumor markers called soluble mesothelin-related peptides (SMRP). These proteins are released into the bloodstream by malignant mesothelioma cells. FDI's mesothelioma assay is a two-step immunoassay that quantitates SMRP in human blood using a standard ELISA microplate sandwich assay format.
MESOMARK Assay is Available in the United States for Humanitarian Use Only (6/5/2007)
Fujirebio Diagnostics has developed the first in vitro test that measures levels of the biomarker mesothelin in human serum to monitor mesothelioma. This enables doctors to monitor patients diagnosed with biphasic or epithelioid mesothelioma, monitor for recurrence in patients following surgery, or for measuring response to therapies. More...
NYU Study Validates Use Of Fujirebio Diagnostics' MESOMARK Test For Monitoring An Asbestos-Linked Cancer (3/10/2007)
There is new hope for the thousands of Americans suffering from mesothelioma, an aggressive form of cancer linked to asbestos exposure. Results from a recent study conducted by researchers at New York University (NYU) School of Medicine show the MESOMARK Assay, the world's first and only in vitro test for monitoring mesothelioma developed by Fujirebio Diagnostics, Inc., is an effective way to measure proteins within the blood that reflect changes in disease. More...
Fujirebo Diagnostics Gets OK for Test (1/25/2007)
A Philadelphia-area company got marketing approval Thursday for a blood test for mesothelioma, a form of cancer liked to asbestos exposure. Fujirebio Diagnostics Inc., a subsidiary of Japanese company Fujirebio Inc., got Food and Drug Administration approval for its Mesomark assay test. More...
Ground-Breaking Mesothelioma Detection Study Begins - Libby, MT Residents Participating in Mesothelioma Applied Research Foundation (MARF) Funded Research into Mesothelioma Serum Marker (9/15/2005)
Exciting new developments using a blood serum marker to detect cancer are being investigated in a longitudinal study in Libby, Montana. In a generous and caring humanitarian act, nearly half of Libby, Montana residents, many of whom have been exposed to asbestos, have agreed to participate in a long term study to calibrate a newly released test for the detection of mesothelioma. Mesothelioma is a malignant tumor that aggressively invades the mesothelial linings of the lungs, abdomen, heart or testicles. More...
Fujirebio Diagnostics Submits Application to FDA For Approval of MESOMARK, the First Blood Test for Mesothelioma (5/2/2005)
Fujirebio Diagnostics, Inc. (FDI), a world-leader in oncology testing, today announced that it submitted a 510K application to the U.S. Food and Drug Administration (FDA) on April 29, 2005 for clearance of MESOMARK(TM), the first blood test for mesothelioma. More...
Mesothelioma Test 'a breakthrough' (4/15/2005)
AUSTRALIAN researchers have developed a world-first blood test which could help in the early detection of mesothelioma, a deadly asbestos-related cancer of the lung lining. About 700 people every year are diagnosed with the disease in Australia, which has the highest reported incidence in the world. More...
Fujirebio Diagnostics Launches First Blood Test for Mesothelioma; Vital Diagnostics to Make Test Commercially Available in Australia (3/2/2005)
Fujirebio Diagnostics, Inc. (FDI), a world-leader in oncology testing, today announced that it has signed a distributor agreement with Australian-based Vital Diagnostics for its new blood test for mesothelioma - MESOMARK(TM). The agreement marks the beginning of the company's commercial roll-out of MESOMARK, which is now available for the first time in Australia. More...